Ironwood Pharmaceuticals, Inc..
IRWD.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Ironwood Pharmaceuticals, Inc. is a commercial biotechnology company focused on developing and commercializing innovative medicines that address unmet needs in gastrointestinal (GI) diseases. The company's key product is LINZESS® (linaclotide), used for the treatment of irritable bowel syndrome with...Show More
Better Health for All
20
Ironwood Pharmaceuticals' core business is focused on developing and commercializing innovative medicines that address unmet needs in gastrointestinal (GI) diseases. Its key product, LINZESS® (linaclotide), treats irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). In June 2023, the company acquired VectivBio's apraglutide, an investigational GLP-2 analog for Short Bowel Syndrome with intestinal failure (SBS-IF), which targets an estimated 18,000 adult patients across the U.S., Europe, and Japan.
1
Fair Money & Economic Opportunity
0
Ironwood Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing medicines, such as LINZESS®. The provided articles detail its financial performance, drug pricing, patient savings programs, and clinical trial activities. There is no evidence that the company engages in lending, insuring, moving, or storing money, nor does it offer consumer credit products or financial services.
1
Therefore, all KPIs related to 'Fair Money & Economic Opportunity' are not applicable to its core business operations as defined by the rubric.
Fair Pay & Worker Respect
20
In 2024, Ironwood Pharmaceuticals reported a CEO-to-median employee pay ratio of 22:1, with the median employee compensation at $277,673.
1
Employee feedback from Glassdoor reviews, based on 98 reviews, shows an overall rating of 3.86 out of 5 stars (approximately 77.2% satisfaction).
2
Additionally, 63% of employees approve of the CEO, and 69% would recommend working at the company to a friend.
3
Fair Trade & Ethical Sourcing
0
No evidence available to assess Ironwood Pharmaceuticals, Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
-10
The company has a comprehensive whistleblower policy, amended and restated on September 25, 2025, which applies to directors, officers, employees, contractors, and third parties.
1
It includes a non-retaliation policy for good faith reporting, explicitly protecting those who report internally or to regulatory agencies.
2
Reporting channels include direct contact with management or the Audit Committee, a global independent third-party compliance hotline (1-800-781-6257) accessible 24/7, and an online portal.
3
Reports are investigated promptly and thoroughly, and records are retained for a minimum of three years.
4
Ironwood has a strict anti-corruption policy that prohibits bribery in any form, including facilitation payments, and refers to a specific Foreign Corrupt Practices Act Policy.
5
The company is committed to abiding by its public disclosure obligations in a full, fair, accurate, timely, and understandable manner, with internal control procedures regulated by the Sarbanes-Oxley Act of 2002.
6
The company received a notification from Nasdaq on March 21, 2025, for non-compliance with Listing Rule 5250(c)(1) due to the late filing of its 2024 Form 10-K.
7
Kind to Animals
-10
Ironwood Pharmaceuticals has a public policy committing to the ethical use of animals in medical research, adhering to the 'Three Rs' (Replace, Reduce, Refine).
1
All animal studies conducted by the company are subject to review by an Institutional Animal Care and Use Committee (IACUC).
2
No War, No Weapons
0
No evidence available to assess Ironwood Pharmaceuticals, Inc. on No War, No Weapons.
Planet-Friendly Business
20
Ironwood Pharmaceuticals has not reported any environmental compliance violations, fines, or regulatory actions across multiple ESG reports and summaries.
1
This indicates an exemplary compliance history. However, the company lacks publicly available quantitative data for all other environmental KPIs, including total greenhouse gas emissions, renewable energy use, water use per revenue, waste diversion rates, and the existence of science-based targets.
2
Information on supply chain climate transparency, biodiversity efforts, and climate-related financial disclosures (like TCFD alignment or climate scenario analysis) is also absent.
3
Respect for Cultures & Communities
0
The provided articles, including the 2021 and 2022 ESG reports, focus on internal diversity, equity, and inclusion initiatives, patient engagement, and general community service. However, they do not contain specific quantitative data or details relevant to the defined KPIs for 'Respect for Cultures & Communities'. There is no information on formal partnerships with indigenous or local community groups, revenue reinvested in local community development, cultural appropriation incidents, cultural impact assessment protocols, local employment ratios, grievance mechanisms for community concerns, community complaint resolution times, FPIC participation rates, community governance inclusion, cultural preservation investment, local procurement share, indigenous supplier engagement, cultural site protection, social license to operate, charitable giving to cultural heritage organizations, community fund allocation, language inclusivity, cultural incident response, or cultural sensitivity training completion.
1
Safe & Smart Tech
30
All employees are required to take monthly, quarterly, and annual cybersecurity training, and participate in quarterly phishing test campaigns.
1
Users have rights to access, rectify, delete, restrict, and object to the processing of their personal data, and can submit requests via email.
2
Regular vulnerability scans are conducted, and critical vulnerabilities are patched within 10-15 days on average. The company maintains compliance with major privacy regulations including GDPR, Swiss Data Protection Act, UK Data Protection Act, CCPA, CPRA, and Washington State’s My Health My Data Act.
3
Zero Waste & Sustainable Products
-40
Ironwood Pharmaceuticals has implemented several waste reduction initiatives, including plastics recycling, compost recycling, and paper recycling programs.
1
The company achieved 90% on-site paper elimination and uses compostable paper and utensils.
2
For hazardous waste, the company eliminated hazardous chemical storage at its new headquarters facility.
3
Furthermore, Ironwood Pharmaceuticals has not reported any waste disposal violations in the past three years.
4